Medical
-
Receptor Life Sciences (RLS) has published data from a Phase 1 PK trial of its RLS103 dry powder cannabidiol (CBD) in the Journal of Pharmaceutical Sciences demonstrating significantly greater bioavailability for the inhaled CBD than for… Read more . . .
-
Virpax Pharmaceuticals said that it is encouraged by the FDA response to its IND for MMS019 “high-density molecular masking spray” which the company is developing as an anti-viral barrier. According to Virpax, the company now intends… Read more . . .
-
Tiziana Life Sciences has published results from a pilot study of its intranasal Foralumab in mild to moderate COVID-19 demonstrating that nasal administration of the human anti-CD3 monoclonal antibody was well tolerated and significantly reduced… Read more . . .
-
According to ReCode Therapeutics, studies of its nebulized lipid nanoparticle DNAI1 mRNA therapy for the treatment of primary ciliary dyskinesia in non-human primates demonstrated that a single dose of the mRNA could be delivered successfully… Read more . . .
-
According to an Insmed update, the company launched recently launched Arikayce amikacin liposome inhalation suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC) in Japan. The Japanese Ministry… Read more . . .
-
Satsuma Pharmaceuticals has initiated the SUMMIT Phase 3 trial of its STS101 dihydroergotamine (DHE) nasal powder for the treatment of migraine, the company said. A previous Phase 3 trial of STS101 called EMERGE failed to… Read more . . .
-
Augmenta Bioworks and TFF Pharmaceuticals have announced that in vitro testing of their AUG-3387 dry powder monoclonal antibody has demonstrated that the mAb neutralizes the SARS-CoV-2 Delta variant, the highly transmissible strain that is currently dominant in numerous… Read more . . .
-
Results from a Phase 1 trial of an inhaled version of CanSino Biologic’s Ad5-nCoV vaccine against COVID-19 have been published online in The Lancet Infectious Diseases. The study enrolled 130 healthy volunteers who got either… Read more . . .
-
Preclinical studies by researchers from the LKS Faculty of Medicine at The University of Hong Kong have demonstrated that a dry powder formulation of tamibarotene delivered to the lungs of hamster and mice has broad… Read more . . .
-
Sorrento Therapeutics has initiated a Phase 2 trial of its CoviDrops intranasal neutralizing antibody in COVID-19 patients in the UK, the company said. The trial is expected to enroll 350 COVID-19 patients who have mild… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.